inclusion criteria: 1. (part a) individual aged between 19-64 years old and willing to provide written informed consent to participate study voluntarily. (part b) individual aged 19 years and above and willing to provide written informed consent to participate study voluntarily. 2. individual fall under one or more of the following; * those who have been at least 16 weeks (112 days) and less than 48 weeks (336 days) without additional covid-19 vaccination since the last covid-19 vaccination. * those who have been at least 16 weeks (112 days) or more and less than 48 weeks (336 days) since the release of quarantine due to covid-19 confirmation. 3. individual with body mass index (bmi) of 30.0 kg/m2 or less at screening visit. 4. individual who agrees with using an effective birth control method for at least 4 weeks before the screening and during the study period. 5. individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, and platelet plasma components) during the study period.

inclusion criteria: 1. (part a) individual aged between 19-64 years old and willing to provide written informed consent to participate study voluntarily. (part b) individual aged 19 years and above and willing to provide written informed consent to participate study voluntarily. 2. individual fall under one or more of the following; * those who have been at least 16 weeks (112 days) and less than 48 weeks (336 days) without additional covid-19 vaccination since the last covid-19 vaccination. * those who have been at least 16 weeks (112 days) or more and less than 48 weeks (336 days) since the release of quarantine due to covid-19 confirmation. 3. individual with body mass index (bmi) of 30.0 kg/m2 or less at screening visit. 4. individual who agrees with using an effective birth control method for at least 4 weeks before the screening and during the study period. 5. individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, and platelet plasma components) during the study period.

inclusion criteria: (part a) individual aged between 19-64 years old and willing to provide written informed consent to participate study voluntarily. (part b) individual aged 19 years and above and willing to provide written informed consent to participate study voluntarily. individual fall under one or more of the following; those who have been at least 16 weeks (112 days) and less than 48 weeks (336 days) without additional covid-19 vaccination since the last covid-19 vaccination. those who have been at least 16 weeks (112 days) or more and less than 48 weeks (336 days) since the release of quarantine due to covid-19 confirmation. individual with body mass index (bmi) of 30.0 kg/m2 or less at screening visit. individual who agrees with using an effective birth control method for at least 4 weeks before the screening and during the study period. individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, and platelet plasma components) during the study period.

inclusion criteria: (part a) individual aged between 19-64 years old and willing to provide written informed consent to participate study voluntarily. (part b) individual aged 19 years and above and willing to provide written informed consent to participate study voluntarily. individual fall under one or more of the following; those who have been at least 16 weeks (112 days) and less than 48 weeks (336 days) without additional covid-19 vaccination since the last covid-19 vaccination. those who have been at least 16 weeks (112 days) or more and less than 48 weeks (336 days) since the release of quarantine due to covid-19 confirmation. individual with body mass index (bmi) of 30.0 kg/m2 or less at screening visit. individual who agrees with using an effective birth control method for at least 4 weeks before the screening and during the study period. individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, and platelet plasma components) during the study period.